Â鶹´«Ã½

Kelsey Goodwin is a director and senior research analyst at Â鶹´«Ã½ covering the biotechnology sector. Prior to joining Â鶹´«Ã½ in June 2025, Goodwin spent nearly seven years at Guggenheim Securities where she was a research analyst covering the oncology sector. Prior to making the transition to Wall Street, Goodwin was a healthcare consultant for IMS Health (now IQVIA) where she worked with many of the world's leading pharmaceutical companies. Goodwin received a bachelor's degree in biology from Bowdoin College.

Universe Coverage

Biotechnology
BCAX	Bicara Therapeutics, Inc.
BDTX	Black Diamond Therapeutics, Inc.
CGON	CG Oncology, Inc.
ERAS	Erasca, Inc.
JANX	Janux Therapeutics, Inc.
LONA	LeonaBio, Inc.
NUVL	Nuvalent, Inc.
OLMA	Olema Pharmaceuticals, Inc.
ORIC	Oric Pharmaceuticals, Inc.
TARA	Protara Therapeutics, Inc.
RLMD	Relmada Therapeutics, Inc.
RVMD	Revolution Medicines, Inc.
SMMT	Summit Therapeutics, Inc.
TNGX	Tango Therapeutics, Inc.
URGN	UroGen Pharma Ltd.